Haemonetics Corporation
HAE
$78.71
$3.835.12%
NYSE
| 03/28/2026 | 12/27/2025 | 09/27/2025 | 06/28/2025 | 03/29/2025 | |
|---|---|---|---|---|---|
| Revenue | 346.35M | 338.97M | 327.32M | 321.39M | 330.60M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 346.35M | 338.97M | 327.32M | 321.39M | 330.60M |
| Cost of Revenue | 148.10M | 136.63M | 132.71M | 129.54M | 131.44M |
| Gross Profit | 198.26M | 202.34M | 194.60M | 191.86M | 199.16M |
| SG&A Expenses | 125.29M | 105.90M | 100.10M | 99.95M | 115.63M |
| Depreciation & Amortization | 10.49M | 10.93M | 11.18M | 11.39M | 11.30M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 298.29M | 267.75M | 258.52M | 256.46M | 275.07M |
| Operating Income | 48.07M | 71.22M | 68.80M | 64.94M | 55.53M |
| Income Before Tax | -28.40M | 59.98M | 51.29M | 45.17M | 70.74M |
| Income Tax Expenses | -8.25M | 15.24M | 12.60M | 11.14M | 12.76M |
| Earnings from Continuing Operations | -20.15M | 44.74M | 38.68M | 34.03M | 57.98M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.15M | 44.74M | 38.68M | 34.03M | 57.98M |
| EBIT | 48.07M | 71.22M | 68.80M | 64.94M | 55.53M |
| EBITDA | 69.29M | 98.60M | 97.05M | 93.70M | 77.04M |
| EPS Basic | -0.44 | 0.96 | 0.81 | 0.71 | 1.18 |
| Normalized Basic EPS | 0.51 | 0.85 | 0.81 | 0.73 | 0.70 |
| EPS Diluted | -0.44 | 0.95 | 0.81 | 0.70 | 1.18 |
| Normalized Diluted EPS | 0.51 | 0.85 | 0.81 | 0.73 | 0.69 |
| Average Basic Shares Outstanding | 46.22M | 46.79M | 47.59M | 48.11M | 49.19M |
| Average Diluted Shares Outstanding | 46.22M | 46.99M | 47.66M | 48.35M | 49.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |